An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...

In particular, our expectations regarding Kisqali in combination with an AI could be affected ... Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting; June 2020; Chicago, USA.

The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...

Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhi ...

Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 ...

Adjuvant ribociclib plus an aromatase inhibitor is now an FDA-approved treatment in HR-positive, HER2-negative stage II and ...

Again, Jake, thanks so much for the time. Really appreciate it. I know we had a chance to catch up at ASCO. This year, you guys had a pretty big presence as you kind of rebooting Lilly Oncology. Maybe ...

Germany’s Bayer (BAYN: DE) has presented detailed results from its Phase III OCEANIC-AF trial for the blood thinner asundexian at the annual meeting of the European Society of Cardiology (ESC). The ...

Kisqali is a prescription drug used with other medications to treat certain kinds of breast cancer. Kisqali can cause side effects that range from mild to serious, such as fatigue, hair loss, and ...

Endocrine and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Guideline Update was developed and written by N. Lynn Henry, MD, PhD; ...